Research programme: small-molecule oral therapeutics - Principia Biopharma

Drug Profile

Research programme: small-molecule oral therapeutics - Principia Biopharma

Alternative Names: IL-17 pathway inhibitors for autoimmune and inflammatory diseases - Principia Biopharma; Oral Bruton's tyrosine kinase (BTK) inhibitor for autoimmune diseases and cancer - Principia Biopharma

Latest Information Update: 02 Jul 2015

Price : $50

At a glance

  • Originator Principia Biopharma
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Fibroblast growth factor receptor antagonists; Interleukin 17 receptor antagonists; Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Haematological malignancies
  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 02 Jul 2015 Preclinical trials in Haematological malignancies in USA (PO)
  • 12 Jan 2015 Preclinical trials in Cancer in USA (PO)
  • 22 Apr 2014 Early research in Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top